J&J Vaginal Mesh Prototype Holds 20% Failure Rate, Premarket Test Reveals
An unbelievable 20 percent of patients, in the span of six months, reported failures of the vaginal mesh device during a test made by Ethicon prior to making the product available to the market. This was the gist of the testimony given by a high ranking official of Johnson & Johnson during the trial of Linda Gross against the giant healthcare manufacturer.
Scott Ciarrocca, the officer in charge in the development of the Gynecare Prolift vaginal mesh device, admitted during his testimony that a test was conducted on this mesh product before officially marketing the Prolift in 2005. He further affirmed that failure rate during these tests exceeded 20 percent which is way above accepted levels.
Lawyers of Linda Gross have highlighted this admission in order to underscore their contention that Johnson & Johnson was negligent in their research or that they deceitfully pushed the Prolift vaginal mesh even with the knowledge of the product’s failure.